1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Ondine Biomedical Inc.

Ondine Biomedical Inc.

OBI.L
Ondine Biomedical Inc.GB flagLondon Stock Exchange
14.75
GBp
-0.15
- -
65.05MMarket Cap
Ondine Biomedical Inc.
OBI.L
(London Stock Exchange)

Recent

price

14.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2003
2004
2005
2006
2007
2008
2009
2010
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
0.03
0.03
0.01
0.19
0.19
- -
- -
- -
0.01
0.03
- -
0.01
0.01
0.04
Revenue per Share
-0.06
-0.76
-0.21
-0.25
-0.24
-0.17
-0.83
-0.4
-0.03
-0.09
-0.07
-0.08
-0.63
-0.1
-0.07
-0.07
-0.07
Basic EPS, GAAP
-0.05
-0.57
-0.21
-0.24
-0.22
-0.15
-0.62
-0.35
-0.03
-0.05
-0.04
-0.03
-0.16
-0.09
-0.07
-0.06
-0.07
Free Cash Flow per Basic Share
- -
0.09
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.66
-1.53
-0.46
-0.64
-0.8
-0.88
-10.64
-7.55
-0.08
-0.17
-0.24
-0.32
0.03
-0.09
-0.14
-0.08
-1.32
Book Value per Share
-0.17
3.82
0.41
0.34
0.19
0.02
0.12
-0.02
-0.05
-0.1
-0.14
-0.17
0.37
0.06
0.01
0.03
-0.04
Tangible Book Value per Share
1
4
41
48
55
61
6
8
195
195
195
195
80
195
197
275
49
Basic Weighted Avg Shares
- -
- -
- -
2
2
1
1
2
- -
- -
- -
2
3
1
1
2
2
Sales/Revenue/Turnover
- -
- -
- -
100
-823.33
-1,105.73
-464.1
-272.72
-1,401.94
-4,432.17
-3,023.28
-886.15
-681.98
-2,940.91
-1,230.67
-948.95
-205.78
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
- -
1
1
- -
Depreciation Expense
- -
-3
-9
-12
-13
-10
-5
-3
-6
-17
-14
-16
-50
-19
-14
-19
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-738.82
-819.34
-1,125.66
-446.06
-212.47
-1,561.65
-4,465.42
-3,014.01
-908.49
-1,949.59
-3,036.36
-1,198
-932.06
-159.67
Profit Margin (%)
- -
16
16
16
10
1
- -
- -
-9
-20
-28
-34
30
11
1
6
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
LT Debt
- -
16
17
17
11
1
1
- -
-7
-18
-26
-34
30
12
2
7
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'10
Mar'17
Jun'17
ST Debt
- -
1
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'10
Mar'17
Jun'17
Total Current Assets
2
1
2
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
3
4
Payables & Accruals
2
2
2
ST Debt
- -
1
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-237.99%
-14.19%
229.83%
Free Cash Flow
18.11%
21.88%
12.08%
Net Income, GAAP
32.58%
33.95%
32.51%
Sales/Revenue/Turnover
41.67%
82.63%
70.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
1
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
2

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.1
2023
- -
- -
- -
- -
-0.07
2024
- -
- -
- -
- -
-0.07

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Bioasis Technologies Inc. (BIOAF)
OncoCyte Corporation (OCX)
Targovax ASA (TRVX.OL)
Rallybio Corporation (RLYB)
Opus Genetics, Inc. (IRD)
Millendo Therapeutics, Inc. (MLND)
Business
Ondine Biomedical Inc. is a biotechnology company specializing in the development and commercialization of therapeutics aimed at improving patient outcomes in critical care, primarily focusing on advanced oxygen biology and inflammation pathways. The company's core product portfolio includes innovative synthetic heme therapies designed to treat acute respiratory distress syndrome (ARDS), severe anemia, and related life-threatening conditions. Ondine's leading product candidates are engineered hemoglobin-based oxygen carriers and heme analogs that enhance oxygen delivery and reduce tissue damage in critically ill patients. These biologic drugs target critical care, surgical, trauma, and emergency medicine segments. Ondine operates predominantly in North America and Europe, leveraging cutting-edge biotechnological research and clinical development expertise. Founded in 2015, the company is headquartered in Toronto, Canada. Ondine collaborates with a range of healthcare providers, research institutions, and strategic partners to accelerate clinical trials and regulatory approvals for its pipeline therapies. In the last 1-2 years, Ondine Biomedical has advanced its clinical development programs significantly, including initiating pivotal Phase 3 clinical trials for its flagship products. The company strengthened its strategic position through new collaborations with key pharmaceutical companies and expanded its operational capabilities to support late-stage development and commercialization efforts. Recent organizational changes have focused on optimizing research and development functions to expedite product pipeline milestones, while exploring potential licensing agreements and market expansion opportunities. No major rebranding or name changes have been reported, while the company remains focused on innovation in critical care therapeutics. Ondine Biomedical's integrated approach encompasses product development, clinical validation, and commercialization readiness in the biopharmaceutical industry.